参考来源：

1.https://mp.weixin.qq.com/s/q8kcYvGS3rDC7MQgIOxOgQ.

2.Dingwei Y, et al. Perioperative SHR-A2102, a novel Nectin-4-targeted antibody-drug conjugate, in combination with adebrelimab for patients with muscle-invasive bladder cancer: results from a phase 2/3 study. 2026 ASCO Oral 4506.

3.https://mp.weixin.qq.com/s/L0w2DThxAweYR4-ck_6mkg.

4.https://mp.weixin.qq.com/s/7McjWW9MMEOxamJsy1jb2g.

5.YAN BI, DAN ZHU, XIAOYING LI, et al. Efficacy and Safety of Oral Ribupatide (HRS9531) in Chinese Adults with Obesity: A Phase 2 Trial. 2026 ADA, 2816-LB.

6.https://mp.weixin.qq.com/s/jsQL3SvvEr1_M4nNxedv5Q.

7.https://mp.weixin.qq.com/s/V40Wf1NY49s2NZrL6nC6rg.

8.https://mp.weixin.qq.com/s/6mR42JZjkNS5JqplH3vrFQ.